Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098201 · ClinicalTrials.gov registry record
Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 5
- Enrollment target
NCT01098201 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 5 participants.
The verdict
NCT01098201 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This open-label pilot study will select subjects who are inadequate responders to methotrexate. These subjects will receive certolizumab subcutaneously on a monthly basis for six months. The study is attempting to determine the following: 1. Is lymphatic flow altered in the extremities of RA patients with an inflamed knee? 2. Is resolution of synovitis associated with a restoration of lymphatic flow and lymph node volume following therapy with certolizumab? 3. Can Doppler ultrasound be used to detect and follow alterations of lymph node size?
Interventions
- DRUG Certolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098201
The ClinicalTrials.gov registry entry for NCT01098201 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab is the first listed.
NCT01098201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01098201 about?
NCT01098201 is a clinical study titled "Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)". This open-label pilot study will select subjects who are inadequate responders to methotrexate. These subjects will receive certolizumab subcutaneously on a monthly basis for six months. The study is attempting to determine the following: 1. Is lymphatic flow altered in the extremities of RA patien...
What is the current status of trial NCT01098201?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01098201?
The interventions under investigation include: Certolizumab (DRUG).
Who is sponsoring clinical trial NCT01098201?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.